Argyle Capital Management LLC Sells 244 Shares of Solventum Co. (NYSE:SOLV)

Argyle Capital Management LLC reduced its stake in shares of Solventum Co. (NYSE:SOLV) by 5.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,168 shares of the company’s stock after selling 244 shares during the quarter. Argyle Capital Management LLC’s holdings in Solventum were worth $275,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Modus Advisors LLC acquired a new stake in Solventum during the fourth quarter worth about $25,000. Stonebridge Financial Group LLC acquired a new position in shares of Solventum in the 4th quarter valued at approximately $26,000. True Wealth Design LLC lifted its holdings in shares of Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after acquiring an additional 471 shares during the period. Crews Bank & Trust acquired a new stake in shares of Solventum during the 4th quarter worth approximately $32,000. Finally, Prospera Private Wealth LLC bought a new position in Solventum in the third quarter valued at approximately $35,000.

Solventum Price Performance

Shares of SOLV stock opened at $83.46 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The business’s 50-day moving average price is $72.25 and its 200-day moving average price is $69.73. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05.

Wall Street Analyst Weigh In

SOLV has been the subject of several recent analyst reports. Morgan Stanley upped their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Mizuho initiated coverage on Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective for the company. Bank of America lifted their target price on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Piper Sandler increased their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $71.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.